Trastuzumab deruxtecan (Enhertu®). HTA ID: 23011

Assessment Status NCPE assessment ongoing
HTA ID 23011
Drug Trastuzumab deruxtecan
Brand Enhertu®
Indication Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Assessment Process
Rapid review commissioned 20/02/2023
Rapid review completed 16/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/03/2023
Pre-submission consultation with Applicant 30/05/2023
Full submission received from Applicant 20/09/2023
Preliminary review sent to Applicant 25/03/2024
NCPE assessment re-commenced 26/04/2024